FINWIRES · TerminalLIVE
FINWIRES
Eli Lilly and Company

Eli Lilly and Company

$LLY
NYSEHealthcare

198 stories mentioning Eli Lilly and CompanyUpdated 2d ago

Eli Lilly trades amid a proposed permanent CMS Medicare drug price negotiation framework; an executive sold $2.88 million in shares per an SEC filing.

What are analysts saying about Eli Lilly and Company?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on Eli Lilly and Company?

Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index down 0.9% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1.1%.The iShares Biotechnology ETF (IBB) fell 1.2%.In corporate news, HCA Healthcare (HCA) shares dropped nearly 3% after Barclays downgraded the stock to equal weight from overweight and cut its price target to $427 from $496.Eli Lilly (LLY) is poised to outpace Q2 consensus sales estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drives franchise performance, RBC said in a note. RBC raised its price target to $1,500 from $1,250. Lilly shares were down 1.5%.AstraZeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to some patients, Bloomberg reported. AstraZeneca shares were shedding 1.8%.Universal Health Services (UHS) shares were down over 3% after Barclays downgraded the company's stock to equal-weight from overweight and adjusted the price target to $179 from $238.

$AZN$HCA$LLY$UHS
Wire

Eli Lilly Could Deliver 'Beat-and-Raise' Quarter, Truist Says

Eli Lilly (LLY) could deliver a "beat-and-raise" second quarter, driven by US prescription growth for Zepbound and Mounjaro, Truist Securities said in a note on Wednesday."We maintain high conviction in Lilly's incretin portfolio," the report said. The Q2 results are due Aug. 5.While current growth stems from Mounjaro/Zepbound, the note pointed to "substantial" potential for Foundayo, its oral obesity treatment, and retatrutide to expand the patient basis."Despite record-shattering revenue, we believe the market remains conservative on the ultimate obesity TAM," the note said. "LLY is well-positioned to capture additional market share over the next decade."Truist raised its price target to $1,370 from $1,281 while keeping its buy rating.Price: $1225.66, Change: $-9.90, Percent Change: -0.80%

$LLY
Sectors

Sector Update: Healthcare Stocks Lower Wednesday Afternoon

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding about 0.8%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Eli Lilly (LLY) is poised to outpace Q2 sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC said in a note. RBC raised its price target to $1,500 from $1,250. Lilly shares were down 1.2%.AstraZeneca (AZN) and Daiichi Sankyo are in advanced talks with England's drug pricing regulator to make the breast cancer medicine Enhertu available to some patients, Bloomberg reported. AstraZeneca shares were shedding 1.8%.Tvardi (TVRD) said Tuesday its phase 1 study confirmed rapid prodrug conversion of TTI-109 to TTI-101, producing nearly identical plasma levels at molar-equivalent doses, and validating its prodrug design. Raymond James upgraded the stock to outperform from market perform. Shares surged 55%.

$AZN$LLY$TVRD
Sectors

Sector Update: Healthcare

Healthcare stocks declined Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each shedding 0.8%.The iShares Biotechnology ETF (IBB) fell 1.5%.In corporate news, Eli Lilly (LLY) is poised to outpace Q2 sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC Capital Markets said in a note. The firm raised its price target on Lilly's stock to $1,500 from $1,250. Lilly shares were down 0.8%.

$LLY
Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says
US Markets

Biopharma Companies' Second-Half Performance to be Largely Driven by Fundamentals, Morgan Stanley Says

Major US biopharmaceutical companies' performance in the second half of the year is likely to be driven largely by fundamentals, as the focus shifts away from economic factors, Morgan Stanley said in a note e-mailed Wednesday.The investment firm revised its price targets for several biopharma stocks it covers ahead of the latest earnings season."The macro has been a key driver of large-cap biopharma performance over the first half of the year," the brokerage said in a note to clients. "Looking into the second half, we expect fundamentals to be more of a driver. We prefer stocks with upside from product cycles and/or pipeline catalysts."Morgan Stanley raised its price target for Eli Lilly (LLY) to $1,347 from $1,344. It expects second-quarter earnings per share of $9.06 for the pharmaceutical giant, compared with Wall Street's estimate of $8.80. The firm projects revenue of $20.78 billion, while the Street is looking for $20.47 billion.The firm expects Johnson & Johnson (JNJ) to deliver a second-quarter beat, with EPS projected at $2.90 and sales at $25.46 billion. Morgan Stanley raised its price target on the stock to $284 from $283.Pfizer's (PFE) second-quarter EPS is seen at $0.69, while the Street is looking for $0.68, according to the note. Revenue is projected at $14.29 billion, while the Street is eyeing $14.44 billion.Moderna's (MRNA) new price target is $39, up from $33 previously. The drugmaker is expected to report a second-quarter loss of $1.85 a share on revenue of $172 million versus the Street's views for a $2.06 loss and sales of $102 million, according to Morgan Stanley.The price target for the Abbvie (ABBV) stock moved to $279 from $278, with Morgan Stanley expecting the company's second-quarter revenue to be ahead of consensus and guidance at $16.88 billion, while EPS is seen at $3.71 versus the Street's forecast of $3.76.Morgan Stanley lowered its price target for Gilead Sciences (GILD) to $166 from $168. The brokerage is projecting a second-quarter loss per share at $7.34, while the Street is looking for a $7.31 loss. Revenue is expected at $7.36 billion, below the $7.41 billion consensus, according to the note.Price: $1228.54, Change: $-7.02, Percent Change: -0.57%

$ABBV$GILD$JNJ$LLY$MRNA$PFE
Wire

Update: Truist Securities Raises Price Target on Eli Lilly to $1,370 From $1,281, Keeps Buy Rating

(Updates to include Truist Securities commentary).Truist Securities raised its price target Eli Lilly (LLY) to $1,370 from $1,281, expecting a potential Q2 beat-and-raise.The pharmaceutical company has strong U.S. script growth for Zepbound and Mounjaro, offset by slower-than-expected Foundayo growth, while maintaining high conviction in the company's incretin portfolio, analysts led by Srikripa Devarakonda wrote in a Wednesday note.Although current growth stems from Mounjaro and Zepbound, there is meaningful upside from Foundayo, particularly in the international market, and from retatrutide as the company expands its patient base, the analysts mentioned.Eli Lilly has an average rating of overweight and mean price target of $1,283.12, according to analysts polled by FactSet.Price: $1228.16, Change: $-7.40, Percent Change: -0.60%

$LLY
Wire

Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says

Biopharma sector's performance in H2 is expected to be driven more by company fundamentals rather than macroeconomic factors, Morgan Stanley said in a note Tuesday.As of July 6, the NYSE Arca Pharmaceutical Index has gained 11% and the Nasdaq Biotechnology Index has added 18%, compared with a 10% gain for the S&P 500 Index, with recent stock performance driven more by changes in valuation multiples than by earnings estimate revisions, the investment bank said.Morgan Stanley said its US Equity Strategy team expects the sector to benefit from broader market leadership. Biotech remains one of the most rate-sensitive sectors, and historically, the sector has delivered nearly 20% annualized returns during falling-rate environments, according to the note.In addition, merger and acquisition activity remains healthy, with several $5 billion to $10 billion deals recently announced, including AbbVie (ABBV) purchasing Apogee (APGE), and Vertex Pharmaceuticals (VRTX) buying Crinetics Pharmaceuticals (CRNX), the investment bank said.Morgan Stanley adjusted its price targets on Biogen (BIIB) to $222 from $224, Amgen (AMGN) to $333 from $340, Gilead Sciences (GILD) to $166 from $168, AbbVie to $279 from $278, Moderna (MRNA) to $39 from $33, BioNTech (BNTX) to $119 from $126, Regeneron Pharmaceuticals (REGN) to $730 from $788, Johnson & Johnson (JNJ) to $284 from $283, and Eli Lilly (LLY) to $1,347 from $1,344.Shares of Biogen, Amgen, Gilead, AbbVie, Moderna, BioNTech, Regeneron, Johnson & Johnson, and Eli Lilly were down 2%, 0.1%, 0.8%, 0.4%, 7%, 1.9%, 1.9%, 0.4%, and 0.5% respectively, in Wednesday trading.Price: $201.67, Change: $-4.03, Percent Change: -1.96%

$ABBV$AMGN$APGE$BIIB$BNTX$CRNX$GILD$JNJ$LLY$MRNA$REGN$VRTX
Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says
US Markets

Eli Lilly Weight-Loss, Diabetes Franchise to Drive Second Quarter Sales Beat, RBC Says

Eli Lilly (LLY) is poised to outpace second-quarter sales consensus estimates as strong volume uptake of its weight-loss drug Zepbound and Mounjaro diabetes treatment drive franchise performance, RBC Capital Markets said in a note Wednesday.The brokerage expects second-quarter revenue of $20.74 billion, ahead of its previous estimate of $20.32 billion and topping the $20.51 billion consensus. Zepbound sales during the quarter are expected to reach $4.81 billion against the $4.57 billion consensus, while Mounjaro revenue is expected to hit $9.34 billion compared with Wall Street estimates of $8.79 billion.The strength in sales of these drugs will offset expected pricing headwinds and lower sales of older products including breast cancer treatment Verzenio, plaque psoriasis treatment Taltz and type 2 diabetes drug Trulicity, according to the note."(Most favored nation) pricing in Medicare remains in effect throughout 2026, predominantly weighing on late-lifecycle products including Taltz, Trulicity, Verzenio and Forteo," RBC analysts Trung Huynh and Justin Burns said.The firm raised its price target on Lilly's stock to $1,500 from $1,250 due to "continued outperformance" of Mounjaro and Zepbound and increased earnings per share estimates for 2026 and 2027 to $37.10 and $49.33 from $36.24 and $42.89."With higher costs we are in line with consensus on (second quarter) earnings," Huynh and Burns wrote. "We anticipate another guidance raise, though not as much as the (first quarter) increase in sales or earnings per share."The drugmaker is scheduled to report its second-quarter financial results Aug. 5.Eli Lilly shares were down 0.4% in Wednesday trading and have gained 14% this year.Price: $1237.64, Change: $+2.08, Percent Change: +0.17%

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.4%.The iShares Biotechnology ETF (IBB) climbed 1.4%.In corporate news, Vertex Pharmaceuticals (VRTX) agreed to buy endocrine disease drugmaker Crinetics Pharmaceuticals (CRNX) for a total equity value of about $10 billion. Crinetics shares jumped 98%, and Vertex was down 1.2%.Eli Lilly (LLY) Canada said Tuesday that Health Canada has approved Mounjaro for pediatric patients aged 10 to 17 with type 2 diabetes. Lilly shares rose 2.7%.Vera Therapeutics' (VERA) Trutakna has been approved to reduce proteinuria in adults with primary immunoglobulin A nephropathy, the US Food and Drug Administration said in a Tuesday statement. Vera Therapeutics shares jumped by more than 7%.AstraZeneca (AZN) has signed an agreement to access Helix's genomic datasets to support research for drug discovery and development, Helix said Tuesday. AstraZeneca shares added 1.4%.

$AZN$CRNX$LLY$VERA$VRTX
Wire

Market Chatter: Eli Lilly, Regeneron Among First Companies in FDA PreCheck Pilot Program

Eli Lilly (LLY) and Regeneron Pharmaceuticals (REGN) are among the first seven companies selected by the U.S. Food and Drug Administration for a pilot program aimed at accelerating reviews of new domestic manufacturing facilities, CNBC reported Monday, citing FDA spokesperson Benjamin Nichols.The other participants in the FDA's PreCheck pilot program are Amneal Pharmaceuticals (AMRX), Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin, the report said.The program allows regulators to begin reviewing new manufacturing facilities while they are still under construction, which the agency estimates could save companies up to 14 months, according to the report.Eli Lilly, Regeneron and FDA did not immediately respond to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $1228.24, Change: $+20.12, Percent Change: +1.67%

$AMRX$LLY$REGN
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. Lilly shares popped 7%.Johnson & Johnson (JNJ) shares gained 4% after the company said Friday that a European Medicines Agency committee recommended expanding Tecvayli's approval in combination with daratumumab for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.Cumberland Pharmaceuticals (CPIX) shares jumped past 9% after the company presented updated phase 2 results showing additional evidence that ifetroban may help protect heart function in patients with Duchenne muscular dystrophy.Acadia Pharmaceuticals (ACAD) shares climbed nearly 8% after it said the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion of Daybu following a re-examination procedure, recommending approval of the drug to treat neurobehavioral symptoms of Rett syndrome in patients aged five and older.

$ACAD$CPIX$JNJ$LLY
Sectors

Sector Update: Healthcare

Healthcare stocks were higher late Friday afternoon, with the NYSE Healthcare Index rising 2.2% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 2.5%.The iShares Biotechnology ETF (IBB) climbed 1%.In corporate news, Eli Lilly (LLY) said Friday that the European Medicines Agency's Committee for Medicinal Products for Human Use has issued a positive opinion for Jaypirca to treat adults with chronic lymphocytic leukemia across all lines of therapy. Lilly shares gained 7.2%.

$LLY
Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Thursday afternoon with the NYSE Healthcare Index gaining 1.7% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 1.6%.The iShares Biotechnology ETF (IBB) advanced 1.3%.In corporate news, Bio-Techne (TECH) shares jumped 20% after the company agreed to be acquired by Germany's Merck in an all-cash deal with an enterprise value of $11.3 billion.Eli Lilly (LLY) shares rose 1% after the company said its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.Kymera Therapeutics (KYMR) shares jumped 16% after the company said it has completed enrollment in a phase 2b trial of KT-621 in moderate to severe atopic dermatitis ahead of schedule.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating postoperative pain treatment, the company said. The shares climbed 13%.

$KYMR$LLY$PRFX$TECH
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Thursday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each adding 1.6%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Bio-Techne (TECH) shares surged nearly 20% after it said Thursday it has agreed to be acquired by Merck KGaA in an all-cash deal with an enterprise value of about $11.3 billion, as the German drugmaker aims to expand its presence in life sciences markets.Eli Lilly (LLY) shares rose 0.5% after it said Thursday its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.PRF Technologies' (PRFX) PRF-110 demonstrated analgesic efficacy comparable to Zynrelef in a preclinical study evaluating post-operative pain treatment, the company said Thursday. Its shares jumped 17%.

$LLY$PRFX$TECH
Wire

Eli Lilly Says Foundayo, Zepbound Available Under Medicare GLP-1 Bridge Program

Eli Lilly (LLY) said Thursday its weight management medicines Foundayo and Zepbound will be available to eligible Medicare Part D patients for $50 a month under the Medicare GLP-1 Bridge program, starting July 1.The program will run through Dec. 31, 2027, the company said.Foundayo or orforglipron, a daily pill, and Zepbound, or tirzepatide, KwikPen for single patient use are approved for adults with obesity, or overweight who also have weight-related medical problems.Lilly said about 20 million Medicare beneficiaries may meet the clinical criteria to access the medicines.Shares of Eli Lilly were up more than 1% in Thursday trading.Price: $1129.54, Change: $+12.28, Percent Change: +1.10%

$LLY
Sectors

Sector Update: Healthcare Stocks Advance Late Afternoon

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.9%.The iShares Biotechnology ETF (IBB) climbed 2.4%.In corporate news, Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were up 0.6%.NRx Pharmaceuticals (NRXP) and two units are facing a lawsuit from Kadima Neuropsychiatry Institute for alleged breach of contract and misrepresentation regarding an acquisition agreement, the psychiatric clinic said Wednesday. NRx Pharmaceuticals shares fell 12%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Its shares were down 2.4%.InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. The shares jumped 10%.

$INMD$LLY$NRXP$PFE
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.5% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2.2%.In corporate news, InMode (INMD) board received an unsolicited acquisition proposal last week for all shares not already owned by M.N. Business Strategy for $16.20 per share in cash, the medical technology firm said Wednesday. Shares jumped 11%.Pfizer (PFE) has been dismissed as a defendant in a lawsuit brought by 45 US states, the District of Columbia, and 4 US territories that accused drugmakers and executives of fixing generic drug prices, Reuters reported. Shares were down 3.1%.Eli Lilly (LLY) and Bayer's pharmaceutical division have backed the Trump administration's call for higher drug prices in Europe, the Financial Times reported. Separately, Lilly said Wednesday it has completed its acquisition of Centessa Pharmaceuticals. Lilly shares were shedding 0.5%.

$INMD$LLY$PFE
Sectors

Sector Update: Healthcare

Healthcare stocks were advancing premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.2% higher and the iShares Biotechnology ETF (IBB) up 0.4%.Absci (ABSI) stock was up 20% after the company priced its underwritten offering of 13.5 million shares at $7.41 apiece, expecting to raise $100 million in gross proceeds. The financing includes participation from Eli Lilly (LLY), Absci said.

$ABSI$LLY
Sectors

Sector Update: Healthcare Stocks Advance in Afternoon Trading

Healthcare stocks rose Tuesday afternoon, with the NYSE Healthcare Index adding 1.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 1.2%.The iShares Biotechnology ETF (IBB) advanced 1.5%.In sector news, the US Justice Department is expected to charge about 450 defendants in alleged healthcare fraud schemes worth more than $6.5 billion, marking its largest coordinated antifraud operation to date, The Wall Street Journal reported, citing federal officials.In corporate news, GE HealthCare Technologies (GEHC) is positioned for accelerating growth, driven by improving innovation, order momentum, and backlog, RBC Capital Markets said in a note. RBC started coverage of the company with an outperform rating and an $80 price target. GE HealthCare shares climbed 4.6%.Eli Lilly (LLY) and Astellas Pharma have entered into two separate asset sale agreements with Sangamo Therapeutics as part of Sangamo's voluntary Chapter 11 reorganization, the genomic medicine company said Tuesday. Lilly shares added 0.4%.Boundless Bio (BOLD) shares surged 85% after the company said it signed a definitive merger agreement with privately held biotech firm Serapha Bio.

$BOLD$GEHC$LLY
Wire

Eli Lilly, Astellas Enter Into Asset Sale Agreements With Sangamo Therapeutics

Eli Lilly (LLY) and Astellas Pharma have entered into two separate asset sale agreements with Sangamo Therapeutics as part of Sangamo's voluntary Chapter 11 reorganization, the genomic medicine company said Tuesday.Lilly's agreement covers Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform and the prion disease program ST-506, while Astellas' agreement involves the the Fabry disease program ST-920, Sangamo said.Lilly and Astellas will serve as "stalking horse" bidders in a court-supervised auction process, Sangamo said.Sangamo said it has secured commitment for debtor-in-possession financing to support ongoing operations.The petition was filed in the US Bankruptcy Court for the District of Delaware.Price: $1107.53, Change: $+3.50, Percent Change: +0.32%

$LLY

Showing 81-100 of 198

Track with the FINWIRES app suite

FolioX
FolioX
Track Eli Lilly and Company in your portfolio
WheelAI
WheelAI
Analyze Eli Lilly and Company options with the wheel strategy
StockInsider
StockInsider
See market sentiment on Eli Lilly and Company